FL-VIRGIN-VOYAGES
9.10.2019 13:04:09 CEST | Business Wire | Press release
Virgin Voyages, the new lifestyle brand set to disrupt the travel industry, today announced its exclusive on-demand champagne delivery service, Shake for Champagne™ . Continuing to create the most irresistible experiences at sea, Virgin Voyages is enabling Sailors to request champagne, anywhere on board Scarlet Lady, with a simple shake of their phone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005133/en/
Those looking to take indulgence to the next level can also treat themselves in the newly revealed luxurious champagne lounge and caviar bar, Sip .
“It is never too early for champagne and there is always something to toast to while aboard Scarlet Lady. We want our Sailors to enjoy a glamorous holiday and what better way to feel like a RockStar than a sip of bubbly whenever and wherever you want it,” said Tom Mcalpin, president and CEO of Virgin Voyages.
SHAKE FOR CHAMPAGNE™
Virgin Voyages is giving its Sailors one more reason to celebrate all of life’s moments with its on-demand delivery service, Shake for Champagne™. When the Virgin Voyages Sailor App is shaken, a secret Virgin Voyages Champagne button is revealed and, with just one press, a bottle of Möet & Chandon Impérial will be delivered to the Sailor.
“There’s nothing more luxurious than having champagne at your beck and call or even a shake. We are committed to creating the world’s most irresistible travel brand, so we thought long and hard about how to help our Sailors effortlessly get a sip of bubbly during their voyage, and presto Shake for Champagne™ was conjured up!” said Nathan Rosenberg, CMO for Virgin Voyages.
Delivered in an eye-catching, gleaming Virgin red champagne bucket, which is sure to make everyone around envious, the service includes a 750ml bottle of Möet & Chandon Impérial with two glasses. Möet & Chandon Impérial is a blend of over 200 crus, mingling the full body of pinot noir with the suppleness of Meunier and the finesse of chardonnay – the perfect pairing for a day or evening sailing in the warm Caribbean sea.
SIP
Sip is a decadent lounge designed to be enjoyed with a chilled glass of bubbles. Featuring a diverse curation of champagne labels, including Moët & Chandon – Virgin Voyages’ featured champagne house. Sailors can opt for a glass of bubbles priced from $9 or splash out on a $1,000 vintage bottle. In a nod to Virgin’s quintessential British heritage and eccentricity, Sip will offer a signature afternoon high tea, which will delight the eyes as well as the taste buds, while celebrating oceanic elements.
Designed by the Virgin Voyages design team, with spatial design by HKS Hospitality Interiors, the lounge was inspired by the glamour and effervescence of champagne. Featuring a long marble bar with rose-gold inlay, Sip encourages Sailors to indulge in one of the most luxurious pairings of them all, champagne and caviar. Gold and rose-pink hues echo the color of the champagnes that will be served, and are beautifully offset by deep watery blues and carrara white marble bars and tables. The deep ocean blue banquette wall and carpet that wraps through the space, will create a chance to revel or relax at all times of day as the ship sails through the ocean’s blue waves.
LIMITED-TIME BOOKING OFFER
Sailors can toast to Virgin Voyages’ inaugural season now through November 30, as those who book April or May sailings will receive a complimentary special Virgin Voyages limited-edition bottle of Möet & Chandon Impérial in their cabin upon their arrival. In addition, Sailors who book now can snag their voyage with half off their deposit. Future Sailors and First Mates are invited to check out Virgin Voyages by visiting www.virginvoyages.com .
ABOUT VIRGIN VOYAGES
Virgin Voyages is a global lifestyle brand committed to creating the world’s most irresistible holiday. With operations in the US, UK, and Europe, Virgin Voyages currently has four ships on order with master shipbuilder Fincantieri.
With its inaugural season scheduled for 2020, Virgin Voyages’ first ship Scarlet Lady was designed to reflect a yacht’s sleek luxury. Featuring spaces designed by some of the top names in contemporary design, Scarlet Lady will be Adult-by-Design, a sanctuary at sea for the 18+ traveler.
A dose of ‘Vitamin Sea’ will be naturally intertwined across the entire ship, with well-being activated through a mix of high-energy moments coupled with relaxation and rejuvenation. The Scarlet Lady will also feature alluring entertainment and 20+ world-class intimate eateries on board. Putting a twist on luxury, which the company refers to as Rebellious Luxe, Virgin Voyages will offer incredible value for its Sailors with all restaurants, group fitness classes, soft drinks, gratuities, WiFi and many more Virgin surprises included within the voyage fare.
Scarlet Lady will sail from Miami to the Caribbean in 2020, hosting more than 2,770 sailors and 1,150 amazing crew from around the world. Keep watch on virginvoyages.com for more updates.
Follow Virgin Voyages:
Instagram: @virginvoyages
Facebook: @virginvoyages
Twitter: @virginvoyages
LinkedIn: Virgin Voyages
YouTube: Virgin Voyages
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005133/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom